Beigene, Ltd. (NASDAQ:ONC) Insider Sells $10,133,481.60 in Stock

Beigene, Ltd. (NASDAQ:ONC) insider Xiaodong Wang sold 41,760 shares of Beigene stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $242.66, for a total transaction of $10,133,481.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Xiaodong Wang also recently made the following trade(s):

• On Tuesday, March 18th, Xiaodong Wang sold 41,760 shares of Beigene stock. The stock was sold at an average price of $261.28, for a total value of $10,911,052.80.
• On Tuesday, March 4th, Xiaodong Wang sold 8,146 shares of Beigene stock. The stock was sold at an average price of $254.58, for a total transaction of $2,073,808.68.

Beigene Stock Down 4.5 %

ONC traded down $10.70 on Wednesday, hitting $228.14. 575,673 shares of the company traded hands, compared to its average volume of 491,784. The firm has a market cap of $22.51 billion, a PE ratio of -27.69, a PEG ratio of 7.73 and a beta of 0.49. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The stock’s 50 day moving average is $246.11. Beigene, Ltd. has a 12-month low of $126.97 and a 12-month high of $287.88.

Beigene (NASDAQ:ONC) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.55). The business had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. On average, research analysts anticipate that Beigene, Ltd. will post -5.82 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on ONC shares. Royal Bank of Canada began coverage on shares of Beigene in a research note on Monday, April 7th. They issued an “outperform” rating and a $312.00 price objective for the company. JMP Securities set a $348.00 price objective on shares of Beigene in a report on Friday, February 28th. Macquarie upped their price objective on Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Bank of America raised shares of Beigene from a “neutral” rating to a “buy” rating and increased their target price for the company from $207.00 to $320.00 in a research report on Monday, March 3rd. Finally, Sanford C. Bernstein set a $259.00 target price on Beigene in a report on Thursday, March 13th.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.